Research Paper Volume 13, Issue 16 pp 20716—20737

N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions

Identification of differentially regulated molecular pathways and m6A-related biological functions. (A, B) Functional annotation of the genes with different expression in frontal (A) and temporal (B) lobes using KEGG pathway. (C–J) Representative differentially regulated pathways are shown by analyzing blood samples. Pathways with increased activation included pathways indicative of Alzheimer's Disease (C) and VEGF signaling pathway (E), pathways with reduced activation included Huntington's Disease (D) and taste transduction (F) in AD group compared with CTL group; (G–J) Pathways with dysregulated activation in MCI group compared with CTL group.

Figure 4. Identification of differentially regulated molecular pathways and m6A-related biological functions. (A, B) Functional annotation of the genes with different expression in frontal (A) and temporal (B) lobes using KEGG pathway. (CJ) Representative differentially regulated pathways are shown by analyzing blood samples. Pathways with increased activation included pathways indicative of Alzheimer's Disease (C) and VEGF signaling pathway (E), pathways with reduced activation included Huntington's Disease (D) and taste transduction (F) in AD group compared with CTL group; (GJ) Pathways with dysregulated activation in MCI group compared with CTL group.